Insulin Aspart is a rapid-acting product originally from multinational Novo Nordisk and is sold globally as NovoLog or NovoRapid. However, locally developed products are gaining in significance ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

Novo Nordisk’s modified insulin holds great ... the risk of hypoglycemia and partly covering the need for fast-acting insulin at mealtime,” the researchers said. “The combination of these ...

Manufacturing delays will cause the Novo Nordisk's Fiasp vials to be in short supply through October, a spokesperson said. Earlier this year, the drugmaker reported shortages of NovoLog insulin.

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...

Novo Nordisk NVO is expected to beat estimates when it reports third-quarter 2024 results on Nov. 6, before the opening bell.

Novo Nordisk has followed suit with reductions of up to 75% from the start of next year. The discount affects several of its older long- and short-acting insulin brands in both vial and pre-filled ...

Biotech is predicted to account for 39% of total spending, surpassing $892 billion by 2028, with rapid ... insulin sales, particularly in North America. TD Cowen reiterated its Buy rating on Novo ...

It has several effects, including slowing down stomach emptying, acting on the brain to reduce appetite and boosting insulin ... by the drugs maker Novo Nordisk, which makes Wegovy.